Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 17
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
Authors Liao X, Ye H, Si T
Received 28 November 2020
Accepted for publication 7 January 2021
Published 11 February 2021 Volume 2021:17 Pages 453—469
DOI https://doi.org/10.2147/NDT.S294521
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Taro Kishi
Xuemei Liao,1,* Hui Ye,2,* Tianmei Si1
1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, People’s Republic of China; 2Medical Department, Sanofi, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tianmei Si
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Huayuanbeilu 51#, Haidian District, Beijing, 100191, People’s Republic of China
Tel +86 13910987793
Email si.tian-mei@163.com
Abstract: Metabolic syndrome (MetS) in patients with schizophrenia occurs 2– 3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various antipsychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients’ metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.
Keywords: antipsychotics, switch, metabolic syndrome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.